- Home
- TRVI
as 01-17-2025 4:00pm EST
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 341.4M | IPO Year: | 2019 |
| Target Price: | $9.31 | AVG Volume (30 days): | 659.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.27 - $4.68 | Next Earning Date: | 11-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Trevi Therapeutics Inc. News
TRVI Breaking Stock News: Dive into TRVI Ticker-Specific Updates for Smart Investing
Zacks
11 days ago
What Makes Trevi Therapeutics (TRVI) a New Buy Stock
MT Newswires
11 days ago
B. Riley Adjusts Trevi Therapeutics' Price Target to $11 From $6, Maintains Buy Rating
PR Newswire
11 days ago
Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
MT Newswires
a month ago
Trevi Therapeutics Prices $50 Million Underwritten Offering
PR Newswire
a month ago
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering
Clinical Trials Arena
a month ago
Trevi’s chronic cough trial in IPF subjects continues without sample size change
MT Newswires
a month ago
Sector Update: Health Care Stocks Softer Thursday Afternoon
MT Newswires
a month ago
Top Midday Gainers
Compare TRVI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRVI Trevi Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.